Physician profile
Christopher Robert Angus
NPI 1457779829
$3,531.68
in general payments reported to CMS, 2019-2025
33 companies · $14.10 in 2025
The $14.10 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $14.09 · 2021: $464 · 2022: $865 · 2023: $1,280 · 2024: $713 · 2025: $14.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,006.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $582.82 | 2022-2024 | Ffrct |
| Boston Scientific Corporation | $523.95 | 2021-2023 | Watchman Access System |
| Pfizer INC. | $349.03 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $201.12 | 2021-2024 | Verquvo |
| Philips North America LLC | $199.30 | 2022-2025 | (Ck4) Mcot, Extended Holter |
| Abiomed | $183.35 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $163.30 | 2023-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.15 | 2021-2024 | Jardiance |
| Amgen INC. | $163.12 | 2021-2023 | Repatha |
| Edwards Lifesciences Corporation | $161.95 | 2021 | |
| Cvrx, INC. | $115.17 | 2023-2024 | Barostim Neo System |
| Inspire Medical Systems, INC. | $97.57 | 2023 | Inspire |
| Novartis Pharmaceuticals Corporation | $89.38 | 2021-2022 | |
| Esperion Therapeutics, INC. | $75.64 | 2021-2024 | Nexletol |
| Cleerly, INC. | $41.11 | 2023 | Cleerly Labs |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $39.60 | 2024 | Wegovy, Ozempic, Rybelsus |
| Actelion Pharmaceuticals US, INC. | $36.59 | 2023 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $36.09 | 2022 | |
| Kestra Medical Technology Services, INC. | $32.42 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $26.43 | 2023 | Camzyos |
| Impulse Dynamics (USA) INC. | $26.14 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $25.52 | 2021-2023 | Farxiga |
| Kiniksa Pharmaceuticals International, Plc | $25.05 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $22.13 | 2024 | |
| Sanofi-Aventis U.S. LLC | $21.61 | 2024 | |
| Amarin Pharma, INC. | $19.32 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.47 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $18.02 | 2024 | |
| Abbott Laboratories | $17.25 | 2022 | |
| Irhythm Technologies, INC. | $15.67 | 2022 | |
| Inari Medical, INC. | $14.97 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Daiichi Sankyo INC. | $14.43 | 2024 | Injectafer |
| Lantheus Medical Imaging, INC. | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Angus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.